KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Operating Leases (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Operating Leases for 7 consecutive years, with $270.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 17.89% year-over-year to $270.6 million, compared with a TTM value of $270.6 million through Dec 2025, up 17.89%, and an annual FY2025 reading of $270.6 million, up 17.89% over the prior year.
  • Operating Leases was $270.6 million for Q4 2025 at Alnylam Pharmaceuticals, up from $223.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $288.6 million in Q2 2021 and bottomed at $223.4 million in Q3 2025.
  • Average Operating Leases over 5 years is $255.8 million, with a median of $256.4 million recorded in 2023.
  • The sharpest move saw Operating Leases dropped 8.32% in 2024, then rose 17.89% in 2025.
  • Year by year, Operating Leases stood at $281.3 million in 2021, then fell by 7.11% to $261.3 million in 2022, then decreased by 6.98% to $243.1 million in 2023, then fell by 5.58% to $229.5 million in 2024, then increased by 17.89% to $270.6 million in 2025.
  • Business Quant data shows Operating Leases for ALNY at $270.6 million in Q4 2025, $223.4 million in Q3 2025, and $224.4 million in Q2 2025.